Table 2.
Univariate Analysis for Factors Associated With Cause-Specific Death, Disease Progression, and Lymphatic Progression Within 5 Years
| Characteristic | Cause-Specific Deatha |
Disease Progressiona |
Lymphatic Progressiona |
|||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Age, yb | 1.42 (0.95–2.12) | .08 | 1.26 (0.93–1.71) | .13 | NA | |
| BMI, kg/m2,b | 0.84 (0.62–1.13) | .24 | 0.98 (0.80–1.21) | .87 | NA | |
| Histologic type | .14 | .11 | .02 | |||
| Endometrioid (n=66) | Ref | Ref | Ref | |||
| Nonendometrioid (n=38) | 1.96 (0.81–4.76) | 1.75 (0.89–3.44) | 3.16 (1.24–8.09) | |||
| FIGO grade | .005 | .006 | .008 | |||
| 1 or 2 (n=54) | Ref | Ref | Ref | |||
| 3 (n=50) | 4.93 (1.63–14.90) | 2.79 (1.35–5.78) | 4.04 (1.43–11.36) | |||
| Myometrial invasion | .15 | .60 | .30 | |||
| None (n=9) | Ref | Ref | Ref | |||
| <50% (n=37) | 0.24 (0.05–1.09) | 0.59 (0.20–1.74) | 0.58 (0.17–1.95) | |||
| ≥50% (n=58) | 0.74 (0.24–2.28) | 0.79 (0.29–2.16) | 0.37 (0.11–1.31) | |||
| High riskc | .003 | .006 | .005 | |||
| No (n=56) | Ref | Ref | Ref | |||
| Yes (n=48) | 5.38 (1.78–16.22) | 2.69 (1.32–5.47) | 4.38 (1.56–12.29) | |||
| Cervical stroma invasion | .04 | .50 | NA | |||
| No (n=90) | Ref | Ref | ||||
| Yes (n=14) | 3.42 (1.06–10.97) | 1.45 (0.50–4.21) | ||||
| Peritoneal cytologic findings | .02 | .27 | NA | |||
| Negative or not sampled (n=71) | Ref | Ref | ||||
| Positive (n=33) | 3.01 (1.24–7.30) | 1.48 (0.74–2.96) | ||||
| No. of pelvic nodes removed | .86 | .66 | .65 | |||
| 0–12 (n=36) | Ref | Ref | Ref | |||
| 13–30 (n=33) | 1.31 (0.35–4.87) | 1.30 (0.51–3.30) | 0.95 (0.29–3.05) | |||
| ≥31 (n=35) | 1.52 (0.35–6.61) | 1.70 (0.54–5.42) | 1.82 (0.38–8.65) | |||
| Positive pelvic nodes | .65 | .16 | .21 | |||
| No, or pelvic LND not done (n=15) | Ref | Ref | Ref | |||
| Yes (n=89) | 1.34 (0.38–4.73) | 2.38 (0.71–7.96) | 3.70 (0.48–28.37) | |||
| Para-aortic LND | .72 | .90 | .33 | |||
| No (n=29) | Ref | Ref | Ref | |||
| Yes (n=75) | 1.32 (0.29–5.94) | 0.94 (0.35–2.51) | 0.54 (0.16–1.86) | |||
| No. of para-aortic nodes removed | .98 | .68 | .21 | |||
| 0–1 (n=34) | Ref | Ref | Ref | |||
| 2–11 (n=34) | 1.15 (0.30–4.49) | 0.68 (0.27–1.73) | 0.60 (0.19–1.85) | |||
| ≥12 (n=36) | 1.17 (0.22–6.24) | 0.63 (0.19–2.11) | 0.23 (0.05–1.19) | |||
| Positive para-aortic nodes | .38 | .09 | .52 | |||
| No, or para-aortic LND not done (n=65) | Ref | Ref | Ref | |||
| Yes (n=39) | 0.66 (0.26–1.68) | 0.53 (0.25–1.11) | 0.73 (0.27–1.92) | |||
| Adjuvant therapy | .07 | .02 | .04 | |||
| Chemotherapy (n=29) | 2.54 (0.85–7.65) | 2.77 (1.20–6.37) | 3.04 (0.99–9.38) | |||
| Chemotherapy and EBRT (n=50) | Ref | Ref | Ref | |||
| EBRT (n=8) | 1.61 (0.31–8.38) | 4.50 (1.54–13.16) | 7.81 (1.81–33.63) | |||
| None or unknown (n=17) | 4.98 (1.45–17.05) | 2.93 (0.98–8.75) | 2.59 (0.49–13.79) | |||
Abbreviations: BMI, body mass index; EBRT, external-beam radiotherapy; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; LND, lymphadenectomy; NA, not analyzed; Ref, reference.
a
Each factor was evaluated in a separate univariate Cox proportional hazards regression model, stratified by cohort (LND vs sentinel lymph node).
b
HR per 10-year increase in age and per 5-unit increase in BMI.
c
High risk defined as grade 3 endometrioid type with myometrial invasion ≥50% or nonendometrioid type.